Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, ...

The UK's MHRA warns against purchasing weight-loss drugs without a prescription due to health risks, amid a global rise in ...

The life sciences industry experienced volatility in 2024, marked by pipeline growth, biologics breakthroughs, and evolving ...

Johnson & Johnson secures EU approval for Rybrevant and Lazcluze combo as first-line NSCLC treatment, based on Phase III MARIPOSA trial data. The approval follows FDA setbacks for a subcutaneous ...

Novartis reports positive Phase III trial results for its gene therapy in spinal muscular atrophy Type 2, plans regulatory ...

India's Parliamentary panel has come down heavily on the National Pharmaceutical Pricing Authority (NPPA) and directed it to ...

Dutch immunology specialist argenx announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) approved Vyvdura ...

The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...

Inmagene Biopharmaceuticals merges with Ikena Oncology to form InmageneBio, focusing on IMG-007, an OX40-targeting antibody ...

AusperBio raises $73 million in series B funding to advance Phase II trials of AHB-137, its antisense oligonucleotide therapy ...

Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for ...